Oragenics Inc. (OGEN)

0.97
0.03 3.30
AMEX : Health Technology
Prev Close 1.00
Open 1.02
Day Low/High 0.92 / 1.03
52 Wk Low/High 0.38 / 4.71
Volume 1.07M
Avg Volume 7.17M
Exchange AMEX
Shares Outstanding 29.16M
Market Cap 30.62M
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Oragenics, Inc. To Present At Upcoming Conferences In October

Oragenics, Inc. To Present At Upcoming Conferences In October

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced it will present and meet with investors at The MicroCap Conference on...

Oragenics, Inc. To Present Data From Its Lantibiotics Program At The Boulder Peptide Symposium Monday, September 24, 2018

Oragenics, Inc. To Present Data From Its Lantibiotics Program At The Boulder Peptide Symposium Monday, September 24, 2018

Oragenics, Inc. (NYSE American:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced that Dr.

Oragenics, Inc. Resumes Phase 2 Clinical Trial Of AG013 In Oral Mucositis Following Positive Routine Safety Review

Oragenics, Inc. Resumes Phase 2 Clinical Trial Of AG013 In Oral Mucositis Following Positive Routine Safety Review

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced it has resumed its Phase 2 clinical trial of AG013, a live biotherapeutic...

Oragenics, Inc. Announces Closing Of $13.8 Million Underwritten Public Offering And Full Exercise Of Over-Allotment Option

Oragenics, Inc. Announces Closing Of $13.8 Million Underwritten Public Offering And Full Exercise Of Over-Allotment Option

Florida-based biopharmaceutical company Oragenics, Inc. (NYSE American: OGEN) (the "Company") today announced the closing of an underwritten public offering of units for gross proceeds of approximately $13.

Oragenics, Inc. Announces Pricing Of $12 Million Underwritten Public Offering

Oragenics, Inc. Announces Pricing Of $12 Million Underwritten Public Offering

Florida-based biopharmaceutical company Oragenics, Inc. (NYSE American: OGEN) (the "Company") today announced the pricing of an underwritten public offering of units for gross proceeds of $12 million, prior to deducting underwriting discounts and...

Oragenics, Inc. Announces Peer-Reviewed Publication Detailing Discovery Of OG716 For C. Difficile Infections

Oragenics, Inc. Announces Peer-Reviewed Publication Detailing Discovery Of OG716 For C. Difficile Infections

Oragenics, Inc. (NYSE American: OGEN) (the "Company"), a clinical stage biotechnology company, today announced the publication of a research paper entitled " OG716: designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile...

Oragenics, Inc. And Texas A&M University System Granted U.S. Patent For Lantibiotic MU1140

Oragenics, Inc. And Texas A&M University System Granted U.S. Patent For Lantibiotic MU1140

Oragenics, Inc. (NYSE American: OGEN) (the "Company"), a clinical stage biotechnology company, today announced that the United States Patent and Trademark Office (USPTO) has granted Oragenics and The Texas A&M University System U.

Oragenics, Inc. Announces Pricing Of $1.8 Million Registered Direct Offering

Oragenics, Inc. Announces Pricing Of $1.8 Million Registered Direct Offering

Florida-based biopharmaceutical company Oragenics, Inc. (NYSE American: OGEN) (the "Company") today announced that it has entered into a securities purchase agreement with certain new institutional investors...

Oragenics Completes Enrollment For The Interim Analysis Cohort In Its Phase 2 Clinical Trial Of AG013 For Oral Mucositis

Oragenics Completes Enrollment For The Interim Analysis Cohort In Its Phase 2 Clinical Trial Of AG013 For Oral Mucositis

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced that it has completed enrollment of the interim...

Oragenics, Inc. Announces Peer Reviewed Publication Examining Efficacy Of Mutacin 1140 Lantibiotic Variants Against Clostridium Difficile

Oragenics, Inc. Announces Peer Reviewed Publication Examining Efficacy Of Mutacin 1140 Lantibiotic Variants Against Clostridium Difficile

Oragenics, Inc. (NYSE American: OGEN) (the "Company"), a clinical stage biotechnology company, today announced the publication of a research paper entitled "Mutacin 1140 Lantibiotic Variants Are Efficacious Against...

Oragenics, Inc. Receives Audit Opinion With Going Concern Explanation

Oragenics, Inc. Receives Audit Opinion With Going Concern Explanation

Oragenics, Inc. (NYSE American: OGEN) today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2017, which was filed on February 16, 2018 with the Securities and...

Oragenics, Inc. Announces Reverse Stock Split

Oragenics, Inc. Announces Reverse Stock Split

Florida-based biopharmaceutical company Oragenics, Inc. (NYSE American: OGEN) (the "Company") today announced a reverse split of its common stock, $0.

Oragenics, Inc. Regains Compliance With NYSE American Continued Listing Standards

Oragenics, Inc. Regains Compliance With NYSE American Continued Listing Standards

Florida-based biopharmaceutical company Oragenics, Inc. (NYSE American: OGEN) (the "Company") today announced receipt of notification from the NYSE American LLC (the "Exchange") that the Company has regained...

Oragenics Announces Closing Of $3.3 Million Preferred Stock Private Placement And $3.4 Million Debt Conversion Into Equity

Oragenics Announces Closing Of $3.3 Million Preferred Stock Private Placement And $3.4 Million Debt Conversion Into Equity

Oragenics, Inc. (NYSE MKT: OGEN), a clinical stage biotechnology company, today announced that it has completed a private placement of $3.

Oragenics To Present At The 19th Annual Rodman & Renshaw Global Investment Conference

Oragenics To Present At The 19th Annual Rodman & Renshaw Global Investment Conference

Oragenics, Inc. (NYSE MKT:OGEN), a leader in the development of novel antibiotics against infectious diseases and innovative treatments for oral mucositis, today announced that it will be featured as a presenting company at...

Oragenics Doses First Patient In Phase 2 Clinical Trial Of AG013 For Oral Mucositis

Oragenics Doses First Patient In Phase 2 Clinical Trial Of AG013 For Oral Mucositis

Oragenics, Inc. (NYSE MKT: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced that the first patient has been dosed in its Phase 2...

Oragenics Announces Completion Of Second Closing Of $3.0 Million Preferred Stock Private Placement

Oragenics Announces Completion Of Second Closing Of $3.0 Million Preferred Stock Private Placement

Oragenics, Inc. (NYSE MKT:OGEN), a clinical stage biotechnology company, today announced that it has completed the second closing contemplated by the previously disclosed securities purchase agreement with three accredited...

Oragenics, Inc. Announces Notification Of Noncompliance With Additional NYSE MKT Continued Listing Standard

Florida-based biopharmaceutical company Oragenics, Inc. (NYSE:MKT: OGEN) (the "Company") today announced receipt of notification from the NYSE MKT LLC (the "Exchange") that the Company is not in compliance with the...

Oragenics Presents Development Of Novel Lantibiotic Against Clostridium Difficile At The ICAAC Conference

Oragenics, Inc. (NYSE MKT:OGEN), a leader in the development of new antibiotics against infectious diseases and developing effective treatments for oral mucositis, today announced a poster presentation at the joint American...

Oragenics Announces $3.0 Million Preferred Stock Private Placement And $2.4 Million Loan

Oragenics, Inc. (NYSE MKT: OGEN), a clinical stage biotechnology company, today announced that it has entered into a securities purchase agreement with three accredited investors, to purchase up to $3.

Oragenics Provides First Quarter 2017 Update

Oragenics, Inc. (NYSEMKT:OGEN.

Oragenics, Inc. Receives Audit Opinion With Going Concern Explanation

Oragenics, Inc. (NYSE:MKT - OGEN.

Oragenics Shareholder Update

Oragenics Shareholder Update

Oragenics, Inc. (NYSE MKT:OGEN.

Oragenics Presents Engineering Of Improved Lantibiotic Variants At American Society For Microbiology (ASM) Conference On Antibacterial Development

Oragenics Presents Engineering Of Improved Lantibiotic Variants At American Society For Microbiology (ASM) Conference On Antibacterial Development

Oragenics (NYSE MKT:OGEN.BC), a leader in the development of new antibiotics against infectious disease and developing effective treatments for oral mucositis, today announced it presented at the American Society for...

U.S. FDA Grants Fast Track Designation for the Development of Oragenics' AG013 for Oral Mucositis

U.S. FDA Grants Fast Track Designation for the Development of Oragenics' AG013 for Oral Mucositis

Oragenics (NYSE:MKT - OGEN.BC), a leader in the development of novel antibiotics against infectious disease and developing effective treatments for oral mucositis (OM), today announced that the U.

Oragenics Receives Supportive FDA Feedback For Initiating A Phase 2 Study Protocol For Oral Mucositis Treatment

Oragenics Receives Supportive FDA Feedback For Initiating A Phase 2 Study Protocol For Oral Mucositis Treatment

Oragenics (NYSE MKT: OGEN.BC), a leader in the development of novel antibiotics against infectious disease and developing effective treatments for oral mucositis (OM) today announced that it has received feedback from the...

Oragenics Selects New Lantibiotic For Further Development In Clostridium Difficile Infections

Oragenics Selects New Lantibiotic For Further Development In Clostridium Difficile Infections

Oragenics (NYSE:MKT - OGEN.BC), a leader in the development of new antibiotics against infectious disease and developing effective treatments for oral mucositis, today announced selection of a second generation...